1. Show article details.

    Harpoon Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference

    GlobeNewswire – 7:30 AM ET 11/16/2020

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference, being held December 1-3, 2020.

  2. Show article details.

    BRIEF-Harpoon Therapeutics Presents Preclinical Data On HPN601

    Reuters – 4:48 PM ET 11/12/2020

    Harpoon Therapeutics Inc (HARP): * Harpoon Therapeutics Inc (HARP) - PRESENTED PRECLINICAL DATA ON HPN601 FOR TREATMENT OF SOLID TUMORS Source text for Eikon: Further company coverage:

  3. Show article details.

    Harpoon Therapeutics Presents Encouraging Preclinical Data for HPN601 EpCAM ProTriTAC™ Program at 35th SITC Annual Meeting

    GlobeNewswire – 4:15 PM ET 11/12/2020

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented preclinical data on HPN601 for the treatment of solid tumors at the 35th Society for Immunotherapy of Cancer virtual annual meeting.

  4. Show article details.

    Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

    GlobeNewswire – 7:30 AM ET 11/09/2020

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming virtual investor conferences: A live audio webcast of the Stifel presentation will be available in the Investors section of Harpoon Therapeutics’ website at www.harpoont...

  5. Show article details.

    BRIEF-Harpoon Abstract For HPN601 EpCAM ProTriTAC Program Accepted For Oral Presentation

    Reuters – 8:16 AM ET 11/05/2020

    Harpoon Therapeutics Inc (HARP): * HARPOON THERAPEUTICS ABSTRACT FOR HPN601 EPCAM PROTRITAC™ PROGRAM ACCEPTED FOR ORAL PRESENTATION AT UPCOMING 35TH SITC ANNUAL MEETING Source text for Eikon: Further company coverage:

  6. Show article details.

    Harpoon Therapeutics Abstract for HPN601 EpCAM ProTriTAC™ Program Accepted for Oral Presentation at Upcoming 35th SITC Annual Meeting

    GlobeNewswire – 7:30 AM ET 11/05/2020

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing novel T cell engagers, announced today that the preclinical data on HPN601 for the treatment of solid tumors has been accepted for oral presentation at the 35th Society for Immunotherapy of Cancer annual meeting.

  7. Show article details.

    BRIEF-Harpoon Therapeutics Reports Third Quarter 2020 Financial Results And Provides Corporate Update

    Reuters – 4:18 PM ET 11/04/2020

    Harpoon Therapeutics Inc (HARP): * HARPOON THERAPEUTICS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE. * Q3 REVENUE $3.9 MILLION VERSUS $1.4 MILLION. * Q3 REVENUE ESTIMATE $5.5 MILLION -- REFINITIV IBES DATA. * QTRLY LOSS PER SHARE $0.53. * Q3 EARNINGS PER SHARE VIEW $-0.50 -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:

  8. Show article details.

    Harpoon Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

    GlobeNewswire – 4:05 PM ET 11/04/2020

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the third quarter ended September 30, 2020 and provided a corporate update.

  9. Show article details.

    Harpoon Therapeutics Appoints Omer Siddiqui as VP Development Operations and Project Management

    GlobeNewswire – 7:30 AM ET 11/03/2020

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the appointment of Omer Siddiqui as Vice President, Development Operations and Project Management.

  10. Show article details.

    ReCode Therapeutics Appoints Julie Eastland as Chief Operating Officer and Chief Financial Officer

    Business Wire – 8:00 AM ET 10/13/2020

    - Veteran life sciences executive brings over 25 years of biotechnology, financial and operations expertise ReCode Therapeutics™, a private biopharmaceutical company pioneering disease-modifying medicines for the treatment of life-limiting respiratory diseases, today announced the appointment of Julie Eastland as chief operating officer and chief financial officer.

  11. Show article details.

    Harpoon Therapeutics to Participate in the Cantor Virtual Global Healthcare Conference

    GlobeNewswire – 4:05 PM ET 09/09/2020

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference.

  12. Show article details.

    Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

    GlobeNewswire – 7:30 AM ET 09/02/2020

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming virtual investor conferences: A live audio webcast of the fireside chat at the Baird conference will be available in the Investors section of Harpoon Therapeutics’ websi...

  13. Show article details.

    Harpoon Therapeutics Names Karin Ann Thacker, M.Sc., VP Regulatory Affairs and Quality Assurance

    GlobeNewswire – 7:30 AM ET 08/26/2020

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the appointment of Karin Ann Thacker, M.Sc., as Vice President, Regulatory Affairs and Quality Assurance.

  14. Show article details.

    Harpoon Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

    GlobeNewswire – 4:05 PM ET 08/05/2020

    SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 -- Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the second quarter ended June 30, 2020 and provided a corporate update.

  15. Show article details.

    Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

    GlobeNewswire – 7:30 AM ET 08/05/2020

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming virtual investor conferences: A live audio webcast of the presentation and panel will be available in the Investors section of Harpoon Therapeutics’ website at www.harpo...

  16. Show article details.

    Harpoon Therapeutics Announces Changes to Board of Directors

    GlobeNewswire – 7:30 AM ET 07/02/2020

    Joanne Viney, Ph.D., brings expertise as an immunologist and veteran biotech executive to the board Drs.

  17. Show article details.

    Harpoon Therapeutics Updates Information for its Participation in Two Upcoming Virtual Conferences

    GlobeNewswire – 7:30 AM ET 06/17/2020

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced new information regarding its participation in two upcoming investor virtual conferences.

  18. Show article details.

    Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

    GlobeNewswire – 7:30 AM ET 06/11/2020

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming virtual investor conferences: A live audio webcast of the fireside chats will be available in the Investors section of Harpoon Therapeutics’ website at www.harpoontx.com...

Page:

Today's and Upcoming Events

No events in the next 90 days

Past Events (last 90 days)

  • Nov
    04

    HARP announced Q3 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.